712 North Inc. Announces Publication of Authoritative Review on OPA1 Pathway and Therapeutic Strategies in Autosomal Dominant Optic Atrophy

May 12, 2026 — 712 North Inc., a pre-clinical pharmaceutical company specializing in mitochondrial medicine, announced today the publication of a new review article entitled “Targeting the OPA1 pathway in Autosomal Dominant Optic Atrophy (ADOA): 25 years from gene discovery to therapeutic strategy” in the peer-reviewed journal Expert Opinion on Therapeutic Targets.

The review, authored by Dr. Marcel V. Alavi, CEO of 712 North, provides a landmark overview of the global progress made since the discovery of the OPA1 gene, synthesizing a quarter-century of research into actionable therapeutic frameworks.

“As we mark 25 years since the identification of the OPA1 gene, the field is entering a critical inflection point,” said Dr. Alavi. “While the slow progression and variability of ADOA present unique challenges, recent changes to the regulatory landscape are uniquely positioned to accelerate clinical development.

712 North continues to lead in the development of personalized mitochondrial medicines, leveraging insights into mitochondrial dynamics to address Alzheimer’s and other age-related and hereditary diseases.

For more information, please visit www.712north.com.